Cite

    Popat, S. et al. (2017). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future oncology. pp. 1159-1171. [Online].